Table 2 Clinical outcomes
Strategy or outcome | G-CSF group | Control group |
|---|---|---|
Patients completing the study | 50 patients | 49 patients |
Conventional infertility treatments in initial and second cycles with or without G-CSF priming | ||
 Live deliveries (% per patient) | 3 a (6.0%) | 0 (0%) |
IVF/ICSI and fresh ET | ||
 Ovarian stimulation (OS) | 47 patients | 49 patients |
 No follicular development induced (% per OS) | 0 (0%) | 1 (2.0%) |
 Numbers of follicles (≥ 16 mm) on the hCG day | 4.2 ± 2.9 | 3.0 ± 1.7 |
 Serum E2 concentrations (pg/mL) on the hCG day | 1820 ± 1200 | 1350 ± 840 |
 Successful oocyte retrievals (% per OS) | 47 (100%) | 48 (98%) |
 No ET for lack of transferrable embryos (% per OS) | 2 (4.3%) | 4 (8.2%) |
 Fresh ETs (% per OS) | 45 (96%) | 44 (90%) |
 Cryopreservation of redundant blastocysts possible (% per OS) | 25 (53%) b | 12 (24%) |
 Clinical pregnancies (% per OS) | 14 (30%) c | 6 (12%) |
 Ongoing pregnancies (% per OS) | 12 (26%) d | 5 (10%) |
 Live deliveries (% per OS) | 9 (19%) | 5 (10%) |
Cryopreserved ET | 21 cycles | 14 cycles |
 Clinical pregnancies (% per cryopreserved ET) | 6 (29%) | 4 (29%) |
 Live deliveries (% per cryopreserved ET) | 4 (19%) | 2 (14%) |
Numbers of cumulative live deliveries (% per patient) | 16 (32%) e | 7 (14%) |